Welcome to our dedicated page for Akebia Therapeut news (Ticker: AKBA), a resource for investors and traders seeking the latest updates and insights on Akebia Therapeut stock.
Akebia Therapeutics, Inc. (Nasdaq: AKBA) is a biopharmaceutical company focused on therapies for people impacted by kidney disease, and its news flow reflects this specialization. Company announcements frequently highlight progress with Vafseo (vadadustat), a once-daily oral hypoxia-inducible factor prolyl hydroxylase inhibitor approved for the treatment of anemia due to chronic kidney disease (CKD) in adults on dialysis for at least three months. Updates include prescribing access among dialysis organizations, clinical trial data such as post-hoc analyses from the INNO2VATE trials, and real-world studies like VOICE and VOCAL that examine mortality, hospitalization, and dosing strategies.
News releases also cover Akebia’s rare kidney disease pipeline, including praliciguat and AKB-097. Investors can follow milestones such as the first patient dosed in a Phase 2 trial of praliciguat for biopsy-confirmed focal segmental glomerulosclerosis (FSGS), plans to evaluate praliciguat in other rare podocytopathies, and the planned Phase 2 basket study of AKB-097 across complement-mediated rare kidney diseases, including IgA nephropathy, lupus nephritis, and C3 glomerulopathy. Additional pipeline updates may involve AKB-9090, a HIF-PH inhibitor entering Phase 1 for acute kidney injury associated with cardiac surgery.
Akebia’s news stream also includes financial results, stock option inducement grants under Nasdaq Listing Rule 5635(c)(4), licensing and supply agreements such as amendments to its Vafseo license with Medice in Europe and certain other countries, and participation in healthcare and investor conferences. For investors tracking AKBA, this news page provides a centralized view of clinical, regulatory, commercial, and corporate developments that shape the company’s kidney disease franchise and pipeline trajectory.
Akebia Therapeutics, Inc. (Nasdaq: AKBA) has announced that it will release its financial results for the second quarter ended June 30, 2021, on August 5, 2021, before markets open. The company will also host a conference call at 9:00 a.m. ET on the same day to discuss the results and recent business developments. Interested parties can listen live by calling (877) 458-0977 domestically or (484) 653-6724 internationally. A replay will be available after the call until August 11, 2021.
Akebia Therapeutics (Nasdaq: AKBA) announced on July 1, 2021, that it granted stock options to 25 new employees, totaling 210,000 shares. These options, priced at $3.79 per share, are in accordance with Nasdaq Listing Rule 5635(c)(4). The options vest over four years, with 25% unlocking after the first anniversary and the remainder vesting quarterly, contingent upon the employees' continued service. Akebia is dedicated to improving the lives of individuals affected by kidney disease.
Akebia Therapeutics (Nasdaq: AKBA) announced upcoming presentations of data from its Phase 3 program for vadadustat at the ERA-EDTA Virtual Congress 2021 from June 5-8, 2021. The abstracts are available online in Nephrology Dialysis Transplantation. Key presentations will focus on the hematologic efficacy of vadadustat for anemia in both dialysis-dependent patients and those with non-dialysis-dependent chronic kidney disease. Vadadustat, a hypoxia-inducible factor prolyl hydroxylase inhibitor, is approved in Japan but not yet in the U.S.
On June 2, 2021, Akebia Therapeutics (Nasdaq: AKBA) announced the granting of stock options to 15 new employees totaling 121,000 shares. The options were issued as inducements for employment and have an exercise price of $3.51, equivalent to the stock's closing price on the grant date. Vesting occurs over four years, with 25% vesting after one year and the remainder quarterly, contingent on continued employment. This grant complies with Nasdaq Listing Rule 5635(c)(4).
Akebia Therapeutics (Nasdaq: AKBA) and Otsuka Pharmaceutical have announced the FDA's acceptance of their New Drug Application (NDA) for vadadustat, aimed at treating anemia due to chronic kidney disease (CKD). This application targets adult patients both on and off dialysis. The FDA assigned a standard review with a Prescription Drug User Fee Act (PDUFA) action date of March 29, 2022. The companies emphasize their commitment to bringing this new oral treatment option to patients, with ongoing collaborations for commercial launch preparations.
Akebia Therapeutics® (Nasdaq: AKBA) reported Q1 2021 financial results, showing total revenue of $52.3 million, a decline from $88.5 million in Q1 2020. Collaboration revenue fell to $21.9 million from $59.3 million last year, while net product revenue increased by 4% to $30.4 million. The net loss widened to $69.6 million from $60.7 million. Notably, the NDA for vadadustat was submitted to the FDA, a key milestone for the company. Cash reserves remain strong at $272.8 million, expected to fund operations beyond the anticipated U.S. launch of vadadustat.
On May 4, 2021, Akebia Therapeutics (Nasdaq: AKBA) announced the grant of stock options to 9 new employees. A total of 197,200 shares were offered, each with an exercise price of $3.19, equal to the stock's closing price on April 30, 2021. The options will vest over four years, with 25% vesting on the first anniversary, and the remainder vesting quarterly. These grants comply with Nasdaq Listing Rule 5635(c)(4), intended to incentivize new hires.
Akebia Therapeutics (Nasdaq: AKBA) announced the publication of its Phase 3 clinical program results for vadadustat in the New England Journal of Medicine. The program evaluated vadadustat's effectiveness in treating anemia due to chronic kidney disease (CKD) in patients on and not on dialysis. A New Drug Application (NDA) was submitted to the FDA for vadadustat recently. The program demonstrated that vadadustat is noninferior to darbepoetin alfa for cardiovascular safety in dialysis patients, but did not meet the same for non-dialysis patients.
Akebia Therapeutics, Inc. (Nasdaq: AKBA) will release its financial results for Q1 2021 on May 10, 2021, prior to market opening. The results will be followed by a conference call at 9:00 a.m. ET to discuss financial outcomes and business highlights. Interested parties can join the call by dialing specific numbers or through a live webcast available on the company's website.
The replay will be accessible until May 16, 2021. Founded in 2007 and based in Cambridge, MA, Akebia focuses on developing therapeutics for kidney disease.
Akebia Therapeutics (Nasdaq: AKBA), a biopharmaceutical company focused on kidney disease, announced that CEO John P. Butler will present at the 20th Annual Needham Virtual Healthcare Conference on April 15, 2021, at 1:30 p.m. ET. A live webcast of the presentation will be available on the company's Investors page, with a replay accessible for 30 days post-conference. Founded in 2007 and headquartered in Cambridge, Massachusetts, Akebia aims to improve the lives of those affected by kidney disease.